Ahead of this year’s SLAS2023 conference in San Diego (which takes place 25 February – 1 March) DDW’s Megan Thomas narrates articles from the DDW SLAS2023 supplement as part of the DDW Events podcast series. This is episode two, Acquiring deeper insights and acceleration with AI. At IBM… Read More
Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland. It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14… Read More
A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD). In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More
Several new products for the life sciences sector have been launched over the last month, from biomarker kits to video-based training platforms. DDW provides an update. Breath Biopsy VOC Atlas – Owlstone Medical The Breath Biopsy VOC Atlas is a catalogue of validated and quantitated… Read More
Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study. Camila Egidio Based on Nakhoda and Olszanski,… Read More
Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study. Camila Egidio Based on Nakhoda and Olszanski,… Read More
Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study. Camila Egidio Based on Nakhoda and Olszanski,… Read More
Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study. Camila Egidio Based on Nakhoda and Olszanski,… Read More
Extensive manipulation, mechanical force and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is the identification of drug targets that are not relevant to the biological process under study. Camila Egidio Based on Nakhoda and Olszanski,… Read More
Extensive manipulation, mechanical force, and labelling methods used to enrich cells activate transcriptional programs that mask molecular profiles truly significant to any underlying disease. The consequence is identification of drug targets that are not relevant to the biological process under study. Based on Nakhoda and Olszanski, 2022 (Addressing Recent Failures… Read More
Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution. As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels. James O’Brien, Vice President Life Sciences at Leica… Read More
Researchers have identified 35 genes associated with long-term Lyme disease that could potentially be used as biomarkers to diagnose patients with the condition. The findings, from the Icahn School of Medicine at Mount Sinai in New York and published in the journal Cell… Read More
Leica Microsystems and Cell Signaling Technology (CST) have announced a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution, allowing researchers to design custom antibody biomarker panels. Backed by a decade of research, the Cell DIVE iterative staining workflow enables the visualisation of over… Read More
News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More
A new method to study the proteins released by cells, which could lead to new biomarkers for diseases including cancer, has been developed by scientists at the Francis Crick Institute and Imperial College London. Biomarkers are valuable tools in diagnosing disease or predicting treatment outcomes, but they are… Read More
Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence. The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an… Read More
